logo
Medical Conditions Found After Others Noticed Symptoms

Medical Conditions Found After Others Noticed Symptoms

Buzz Feed3 days ago

Ever thought something was perfectly normal about your body, only to find out it's actually a medical condition? You're not alone. Recently, we asked the BuzzFeed Community to share medical conditions they didn't know they had until someone else pointed out a symptom — and their stories prove that sometimes, the most important medical observations can come from the people around us, not only doctors. Here are some of the most eye-opening responses:
"I know it's a common issue, but I had a friend say he thought I was depressed. I thought, I'm not sad, therefore I'm not depressed. It took me years after that comment to learn he was right and seek help. Now I'm happily on antidepressants and doing so much better than before."
—madds2016
"One of my friends posted about her recent Hashimoto's diagnosis and shared an infographic with a list of common symptoms. I ran down the list and found myself checking a lot of boxes. I went to my primary care doctor shortly after to have labs run, and sure enough, I had the exact same condition! That friend indirectly saved my life in a way."
"When I was in college, I mentioned to a teammate on my cross country team that I couldn't sleep because my mind would race — just so many thoughts that kept me up. She suggested I had ADHD. My twin brother has it, and it's genetic. He was diagnosed around age 6 or 7. I was 29."
"Now I'm medicated and sleep like a rock (mostly) every night."—madds2016
"Since I was a teen, I'd tell people I was allergic to the cold. My skin would get super itchy and come out in blotches and dry patches. Everyone laughed when I said I was allergic to a temperature. I'm 31 now. Two years ago, I went to the doctor for something unrelated. He saw the patches on my skin and immediately diagnosed me with psoriasis, an autoimmune skin disorder. And guess what? Cold temperatures make it worse."
"Hormonal dysfunction. I'm a woman who, since puberty, had severe acne and heavy periods — like changing a pad every two minutes. I also needed way more food to feel full. I went to a gynecologist at 15, but he said it was normal, so I believed him. When I was in my 30s, my mom saw my (very hairy) unshaven legs and said, 'THIS is not normal!' We ran tests. Turns out, I had way too much testosterone. For reference: Women's levels should be between 0.08 and 0.48. Mine was 0.54."
"I'm now on birth control and life has never been better. I never realized anything was wrong because it had always been that way — the periods, the hair, the acne, the appetite. I even thought I just didn't have a waistline. Nope, it was hormonal weight gain. I have one now."—mudda8139
"Autism. Everyone said my son was just like me when I was little. He had already received an autism diagnosis, so I had myself tested too — and I'm autistic as well."
"Ehlers-Danlos Syndrome! I had someone gently suggest that I get checked out (after years of unexplained symptoms) and boom, I was a textbook case."
"ADHD. I didn't know I had it until my daughter was diagnosed as a teenager. We were discussing her symptoms, and I realized, 'Hey, that sounds like me.'"
—abourque
"I thought everyone had TV static vision. Nope. Turns out I just have Visual Snow Syndrome. I figured it out when I randomly read an article about it, and I was like, 'Hey, wait a minute…' It was like the internet pointed it out to me."
"My wife and I did foster care for 10 years. When one of our foster kids came through with severe food insecurity issues, my wife explained all the signs we needed to watch for. As she went through the list, I realized I had all of those issues myself. My wife inadvertently diagnosed me with food insecurity from my childhood."
"I was having really bad back pain from an unrelated injury, and during an X-ray, the medical team noticed spots on my lungs. At first, they thought it was lung cancer, which scared the crap out of me. After a lung biopsy, the doctor showed me pictures of my bronchial tract and said, 'See all those white dots? That's supposed to be pink.' Without that observant radiologist spotting something completely unrelated to what I came in for, I might never have known I had sarcoidosis."
—abourque
"I always thought I was allergic to my own sweat and working out, since I would break into hives! I didn't know what was happening until a medical professional diagnosed me with spontaneous urticaria — an autoimmune issue where my body produces too much histamine. It turns out I'm triggered by sudden temperature changes, not sweat. If it's a really hot day and I jump into the ocean, I'll break out. If it's a cold day and I'm wearing a coat but my legs are exposed, my legs will break out! I have to get injections every month."
"When I was younger, I had some GI issues. The radiology reports showed my appendix was on the left side due to genetic malrotation of the colon. The doctor didn't bother telling me, but I overheard him tell his nurse. A few years later, I had pain on the left side and they suspected chronic appendicitis. But when they did surgery, the pathology reports showed my appendix had endometriosis."
"Many years ago, when I was experiencing severe migraines, I had several scans done on my head to rule out any internal cause. When the results came back, the doctor asked if I had ever hit my head and lost consciousness. I said no, not that I recall. Apparently, I must have had some kind of brain trauma I don't remember, because they explained that my right frontal lobe was atrophied. The migraines eventually went away on their own, but that doctor's observation about my brain explained a lot about my impulse control issues that I never understood before."
—christines442ed4b4e
"I had what they call 'silent' endometriosis. It's far from silent now, but I had absolutely no symptoms for years. I only found out because a surgeon discovered it unexpectedly when I went in for a completely unrelated procedure to get my tubes tied."
Have you ever discovered a medical condition after someone pointed out a symptom you didn't realize was unusual? Share your story in the comments below! And remember, if someone's ever pointed something out, or if something feels off to you, it's always worth asking questions. You never know what you might uncover.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments
Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments

Business Wire

time21 hours ago

  • Business Wire

Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments

HOUSTON--(BUSINESS WIRE)-- Qbtech, the global leader in objective ADHD testing, announces the formation of its Houston-based clinical research and strategic partnership teams, along with new staff appointments and promotions at the company's US headquarters. The employee expansions bolster the company's continued growth in the region, enhancing its capabilities and market presence as it continues to develop and enhance its software solutions. Former clinical research manager Ragini Sanyal has been promoted to Head of Clinical Research, with Jonas Bäckström joining as Chief Strategic Partnership Officer and Jack Smith as Head of US Commercial Operations. As Head of Clinical Research, Sanyal will lead the formalized clinical research team and its efforts to study the clinical utility and validity of objective ADHD assessments for diagnosing ADHD and its benefits in post-treatment follow-up. 'I truly believe objective ADHD technology is a guiding light through the uncertainty of the mental health space. I'm so excited to take on this role and lead our newly structured clinical research team to curate and share the data behind our objective assessments and how they can be used to progress ADHD care,' says Sanyal. 'This new team structure allows us to streamline our efforts across clinical operations, data management, medical writing, and trial execution. It will also help simplify decision-making, improve cross-functional collaboration, and provide a clearer focus as we continue to expand both our team and our portfolio. Coming off the World Congress on ADHD, I am so proud that our team was able to present four meaningful posters, and I can only imagine what we will accomplish in the coming months and years.' Jonas Bäckström, a former member of Qbtech's Board of Directors, has joined as Chief Strategic Partnership Officer, leading the newly established partnerships department from the Houston office. He brings a strong background in digital innovation, having worked with a pioneering digital healthcare provider in Sweden prior to joining Qbtech. 'This is an exciting opportunity for both me and Qbtech,' says Bäckström. 'I look forward to focusing on building scalable, evidence-based business models in the ADHD space and linking telehealth innovation with clinical, payer, and employer ecosystems. With my experience in business development and digital health, I am eager to help our partners achieve sustainable growth, improve patient outcomes, and shape a smarter, more accountable future for mental health, starting with ADHD.' Jack Smith will serve as Head of US Commercial Operations, leading efforts across sales and clinical support to drive Qbtech's expansion and identify new growth opportunities. A military veteran, Smith has served in various roles within the healthcare industry for more than 25 years. "I'm thrilled to be joining Qbtech at such a pivotal time in the US ADHD market. My goal is to build a world-class sales team that delivers real value to clinicians by driving improved patient outcomes through objective, evidence-based tools,' says Smith. 'As awareness grows and underserved markets expand, we have a unique opportunity to empower physicians with the confidence they need to make accurate ADHD diagnoses." The Qbtech team plans to hire additional staff in the Houston office throughout the year. Available career opportunities can be found at Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit

Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments
Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments

Yahoo

time21 hours ago

  • Yahoo

Qbtech Expands US Presence with Formation of New Houston-Based Teams and Staff Appointments

Addition of clinical research and strategic partnership teams marks another milestone for Qbtech in North America, bolstering the company's regional capabilities and footprint HOUSTON, June 02, 2025--(BUSINESS WIRE)--Qbtech, the global leader in objective ADHD testing, announces the formation of its Houston-based clinical research and strategic partnership teams, along with new staff appointments and promotions at the company's US headquarters. The employee expansions bolster the company's continued growth in the region, enhancing its capabilities and market presence as it continues to develop and enhance its software solutions. Former clinical research manager Ragini Sanyal has been promoted to Head of Clinical Research, with Jonas Bäckström joining as Chief Strategic Partnership Officer and Jack Smith as Head of US Commercial Operations. As Head of Clinical Research, Sanyal will lead the formalized clinical research team and its efforts to study the clinical utility and validity of objective ADHD assessments for diagnosing ADHD and its benefits in post-treatment follow-up. "I truly believe objective ADHD technology is a guiding light through the uncertainty of the mental health space. I'm so excited to take on this role and lead our newly structured clinical research team to curate and share the data behind our objective assessments and how they can be used to progress ADHD care," says Sanyal. "This new team structure allows us to streamline our efforts across clinical operations, data management, medical writing, and trial execution. It will also help simplify decision-making, improve cross-functional collaboration, and provide a clearer focus as we continue to expand both our team and our portfolio. Coming off the World Congress on ADHD, I am so proud that our team was able to present four meaningful posters, and I can only imagine what we will accomplish in the coming months and years." Jonas Bäckström, a former member of Qbtech's Board of Directors, has joined as Chief Strategic Partnership Officer, leading the newly established partnerships department from the Houston office. He brings a strong background in digital innovation, having worked with a pioneering digital healthcare provider in Sweden prior to joining Qbtech. "This is an exciting opportunity for both me and Qbtech," says Bäckström. "I look forward to focusing on building scalable, evidence-based business models in the ADHD space and linking telehealth innovation with clinical, payer, and employer ecosystems. With my experience in business development and digital health, I am eager to help our partners achieve sustainable growth, improve patient outcomes, and shape a smarter, more accountable future for mental health, starting with ADHD." Jack Smith will serve as Head of US Commercial Operations, leading efforts across sales and clinical support to drive Qbtech's expansion and identify new growth opportunities. A military veteran, Smith has served in various roles within the healthcare industry for more than 25 years. "I'm thrilled to be joining Qbtech at such a pivotal time in the US ADHD market. My goal is to build a world-class sales team that delivers real value to clinicians by driving improved patient outcomes through objective, evidence-based tools," says Smith. "As awareness grows and underserved markets expand, we have a unique opportunity to empower physicians with the confidence they need to make accurate ADHD diagnoses." The Qbtech team plans to hire additional staff in the Houston office throughout the year. Available career opportunities can be found at About Qbtech Founded in 2002, Qbtech is a privately-owned Swedish company that has developed leading solutions and products for improving the identification, diagnosis, treatment, and follow-up of patients living with ADHD. Qbtech has operations in 14 countries and has offices in Stockholm, Houston, and London. Qbtech is an award-winning company recognized for its innovation, most recently winning the 2022 HSJ Partnership Award for the 'Best Mental Health Partnership with the NHS.' For more information about Qbtech, visit View source version on Contacts Media Contact: Hilari Barton, Trevelino/KellerHnbarton@ 404-214-0722 x 130

CCHR Warns: Millions of Children Exposed to Risky Psychiatric Drugs
CCHR Warns: Millions of Children Exposed to Risky Psychiatric Drugs

Associated Press

timea day ago

  • Associated Press

CCHR Warns: Millions of Children Exposed to Risky Psychiatric Drugs

LOS ANGELES, Calif., June 2, 2025 (SEND2PRESS NEWSWIRE) — A federal assessment of children's health has identified the widespread prescribing of psychotropic drugs to U.S. youth as a 'public crisis' driven by industry profit motives, flawed science, and systemic conflicts of interest. The U.S. Department of Health and Human Services (HHS) found that stimulants, antidepressants, antipsychotics, and anti-anxiety drugs were leading the surge.[1] According to the Citizens Commission on Human Rights International (CCHR) , a mental health industry watchdog, this is fueling a psychotropic drug market that reaps $22.6 billion annually. CCHR advised parents to become better informed about the risks of psychotropic drugs, including benzodiazepines or anti-anxiety drugs prescribed to children. CCHR offers a 16-page educational booklet, Psychiatric Drugs & Your Child's Future , and the documentary Dead Wrong , which features bereaved parents who lost children to psychiatric drug effects, especially antidepressants—black box-warned for suicide in 2004, more than 15 years after Food and Drug Administration (FDA) approval. HHS reported that prescriptions for stimulants rose 250% between 2006 and 2016. By 2022, 11% of all children—and nearly 25% of boys—had a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), despite no medical test to confirm the behavioral symptoms. Long-term trials of ADHD drugs show no academic, behavioral, or social benefit beyond 14 months—and a loss of height averaging one inch. Teen use of antidepressants increased 1,400% between 1987 and 2014, and over 2 million prescriptions were written for adolescents in 2022 alone.[2] Antipsychotic drug use among children grew 800% between 1995 and 2009, with 66% prescribed off-label—including for ADHD and 'aggression.' Antipsychotics in adolescent boys may cause up to 5x more gynecomastia (male breast growth); 4x more extrapyramidal effects (movement disorders); and 6–8x more weight gain than placebo. Meanwhile, serious side effects—including seizures, cardiac issues, male breast growth, and prolonged withdrawal syndromes—are widely documented.[3] CCHR, which has tracked what it calls mass-prescribed drug child abuse since its founding in 1969, said the situation is even more dire than the HHS report reveals. Using data from IQVia's Total Patient Tracker Database for 2020, CCHR found: 1 million 0–17-year-olds were prescribed ADHD stimulants, 15 million were on antidepressants, 15 million were taking anti-anxiety drugs, including highly addictive benzodiazepines, and 829,372 were prescribed antipsychotics known to cause neurological damage.[4] Combined, over 6.1 million children and teens were drugged—representing more than 8.2% of the U.S. youth population.[5] Psychotropic polypharmacy is especially prevalent among youth covered by Medicaid. A 2024 study found a rise in multiple drug use in this group, increasing the risk of adverse medical outcomes. Researchers reviewed 126,972 Medicaid recipients who had received at least one psychotropic drug and had continuous coverage for 90+ days. The prevalence of polypharmacy rose from 4.2% in 2015 to 4.6% in 2020, with higher rates among those in foster care (10.8% to 11.3%), the Children's Health Program (2.2% to 2.8%), and low-income households (2.1% to 2.8%).[6] The problem is exacerbated by drug misuse. In 2018, almost 16% of U.S. college students said they misused prescription stimulants.[7] A 2023 survey of college students who reported using prescription stimulants revealed that about 21.7% had taken a higher-than-prescribed dose in the past three months.[8] Many students mistakenly believe one ADHD stimulant to be no more harmful than coffee, assuming it is safe because it's prescribed by doctors.[9] Youth drug overdoses on prescription drugs is also a serious risk. In 2019, 4,777 U.S. youth died from drug overdoses; 727 involved benzodiazepines and 902 involved psychostimulants. In 2020, 2,928 nonfatal benzodiazepine overdoses were reported among youth aged 15 to 24. Among these, 29% had a prescription in the previous month and 42% within six months. Intentional overdoses were more likely among those with recent prescriptions. Fifty-six percent of benzodiazepine overdoses were intentional compared with 40% of stimulant overdoses.[10] The FDA issued a black box warning in 2020 for benzodiazepines, citing 'risks of abuse, misuse, and addiction, which can lead to overdose or death.'[11] A 2022 study in Pediatrics found that a quarter of insured teens who overdosed on anxiety or ADHD drugs had received a recent prescription.[12] HHS linked the rise in drug use to broadened diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), expanded in 2013 by panels with financial ties to the pharmaceutical industry. This contributed to a 40-fold increase in childhood diagnoses such as ADHD and bipolar disorder. Yet, no psychiatric-defined disorder meets the scientific definition of a disease. Former U.S. National Institute of Mental Health Director Thomas Insel stated: 'Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure.'[13] CCHR, established in 1969 by the Church of Scientology and professor of psychiatry, Dr. Thomas Szasz, has achieved significant reforms in this area, including a 2004 federal law prohibiting schools from forcing students onto psychotropic drugs as a requisite for their education. Jan Eastgate, President of CCHR International, said: 'Profit-driven psychiatry is putting children at risk with no science to justify diagnoses or drugs.' CCHR stresses that the nation's child mental health system requires a complete overhaul—eliminating treatments that expose children to suicide, addiction, physical harm, and institutional profiteering. To learn more, visit: Sources: [1] 'Making Our Children Healthy Again,' Make America Healthy Again Commission (MAHA), 22 May 2025, p. 54 [2] MAHA Report, pp. 16-17 [3] MAHA Report, pp. 54-56 [4] [5] [6] 'Psychotropic Polypharmacy Trends Rise Among Child, Adolescent Medicaid Beneficiaries,' Psychiatric Times, 21 May 2024 [7] [8] [9] 'Are You Surprised By the 4 Most Abused Study Drugs?' 28 Feb. 2018 [10] ; [11] ; 'FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class. Includes potential for abuse, addiction, and other serious risks,' FDA, 23 Sept. 2020 [12] [13] 'The NIMH Withdraws Support for DSM-5,' Psychology Today, 4 May 2003 MULTIMEDIA: Image link for media: Image caption: 'Profit-driven psychiatry is putting children at risk with no science to justify diagnoses or drugs.' – Jan Eastgate, President of CCHR International. NEWS SOURCE: Citizens Commission on Human Rights Keywords: Religion and Churches, Citizens Commission on Human Rights, CCHR International, CCHR International, Jan Eastgate, psychotropic drug market, LOS ANGELES, Calif. This press release was issued on behalf of the news source (Citizens Commission on Human Rights) who is solely responsibile for its accuracy, by Send2Press® Newswire . Information is believed accurate but not guaranteed. Story ID: S2P126647 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store